Replies to post #210708 on Biotech Values

[DewDiligence]

ABT 1Q17 sales by business segment:

 
 Medical devices* 39% 
 Nutrition        27% 
 Diagnostics      19% 
 Pharmaceuticals† 15% 

*Including STJ and diabetes care.

†100% ex-US branded generics.

[DewDiligence]

ABT (+3%—all-time-post-ABBV high) on 2Q17 results:

https://finance.yahoo.com/news/abbott-reports-second-quarter-2017-114500730.html

ABT raised 2017 non-GAAP EPS guidance to $2.43-2.53 (from the prior range of $2.40-2.50).

Note: ABT closed the acquisition of STJ in Jan 2017 and expects to close the acquisition of ALR during 3Q17.